Peter Bohlen
Affiliations: | Hearing and Speech Sciences | Vanderbilt University, Nashville, TN |
Google:
"Peter Bohlen"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wu Y, Hooper AT, Zhong Z, et al. (2006) The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. International Journal of Cancer. 119: 1519-29 |
| Miller DW, Vosseler S, Mirancea N, et al. (2005) Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants. The American Journal of Pathology. 167: 1389-403 |
| Vincent L, Kermani P, Young LM, et al. (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. The Journal of Clinical Investigation. 115: 2992-3006 |
| Lamszus K, Brockmann MA, Eckerich C, et al. (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4934-40 |
| Vincent L, Jin DK, Karajannis MA, et al. (2005) Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Research. 65: 3185-92 |
| Loizos N, Xu Y, Huber J, et al. (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Molecular Cancer Therapeutics. 4: 369-79 |
| Lu D, Zhang H, Koo H, et al. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity Journal of Biological Chemistry. 280: 19665-19672 |
| Vosseler S, Mirancea N, Bohlen P, et al. (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Research. 65: 1294-305 |
| May C, Doody JF, Abdullah R, et al. (2005) Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood. 105: 4337-44 |
| Pauli SA, Tang H, Wang J, et al. (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 146: 1301-11 |